ataluren: Clinical Trials

10 trials of ataluren, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 terminated. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Completed 6, Terminated 4

Follow ataluren: new trials by email Literature Review of ataluren trials Research Report on ataluren

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
Ataluren, PLACEBO - Muscular Dystrophy, Duchenne, Muscular Dystrophies
Phase 3CompletedPTC Therapeutics3602017-07-062026-03-10
Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis
Ataluren - Cystic Fibrosis
Phase 3TerminatedPTC Therapeutics2462015-08-312020-04-27
Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
Ataluren (PTC124®), Placebo - Cystic Fibrosis
Phase 3CompletedPTC Therapeutics2792014-08-012020-05-14
Study of Ataluren (PTC124) in Cystic Fibrosis
Ataluren - Cystic Fibrosis
Phase 3TerminatedPTC Therapeutics612014-05-232020-03-25
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Ataluren - Muscular Dystrophy, Duchenne, Muscular Dystrophies
Phase 3TerminatedPTC Therapeutics2192014-03-202020-08-11
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
Ataluren, Placebo - Muscular Dystrophy, Duchenne, Muscular Dystrophies
Phase 3CompletedPTC Therapeutics2302013-03-262020-08-04
Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada
Ataluren - Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Phase 3CompletedPTC Therapeutics942012-05-202020-11-25
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
Ataluren - Duchenne Muscular Dystrophy
Phase 3TerminatedPTC Therapeutics2652010-11-222026-10-08
Extension Study of Ataluren (PTC124) in Cystic Fibrosis
Ataluren - Cystic Fibrosis
Phase 3CompletedPTC Therapeutics1912010-08-122020-10-19
Study of Ataluren (PTC124™) in Cystic Fibrosis
Ataluren, Placebo - Cystic Fibrosis
Phase 3CompletedPTC Therapeutics2382009-09-082020-05-14

Conditions studied

Cystic Fibrosis (5)  ·  Muscular Dystrophy, Duchenne (5)  ·  Genetic Diseases, Inborn (3)  ·  Genetic Diseases, X-Linked (3)  ·  Muscular Diseases (3)  ·  Muscular Disorders, Atrophic (3)  ·  Muscular Dystrophies (3)  ·  Musculoskeletal Diseases (3)  ·  Nervous System Diseases (3)  ·  Neuromuscular Diseases (3)

Sponsors

PTC Therapeutics (10)

Countries

Canada (9)  ·  United States (9)  ·  Belgium (8)  ·  France (8)  ·  Israel (8)  ·  Italy (8)  ·  Spain (8)  ·  Germany (7)  ·  United Kingdom (7)  ·  Australia (6)  ·  Sweden (6)  ·  Brazil (5)  ·  Poland (5)  ·  Bulgaria (4)  ·  Netherlands (4)

Top investigators

Joseph McIntosh, MD (3)  ·  Temitayo Ajayi, MD (2)  ·  Vinay Penematsa, MD (2)  ·  Edward O'Mara, MD (1)  ·  Francesco Bibbiani, M.D. (1)  ·  Robert Spiegel, M.D. (1)

Results publications

PMID 36866921, PMID 17389552, PMID 17450125, PMID 24836205, PMID 28728956, PMID 30135256, PMID 31983658, PMID 32682670, PMID 32851872, PMID 34383312, PMID 34693725, PMID 34791888, PMID 41879641

NIH funding

2008 (1)